-
Huadong Medicine’s HDM1002 Receives FDA Approval for Clinical Trials
•
Huadong Medicine Co., Ltd (SHE: 000963), a leading China-based pharmaceutical company, has announced that it has received clinical trial approval from the US Food and Drug Administration (FDA) for its investigational drug HDM1002. This small molecule is a complete agonist of the GLP-1 receptor with oral activity, known for its…
-
Rona Therapeutics and Keymed Biosciences Collaborate on siRNA Therapeutics for Glomerulonephritis
•
China-based Rona Therapeutics Inc. and Keymed Biosciences (HKG: 2162) have unveiled a strategic collaboration aimed at the joint discovery and development of first-in-class siRNA therapeutics targeting glomerulonephritis, a group of severe kidney diseases. Rona will apply its proprietary RAZOR RNAi platform to identify siRNA lead compounds directed at a novel…
-
Omron Healthcare and JD Healthcare Form Partnership to Innovate Chronic Disease Management
•
At the China International Medical Equipment Fair (CMEF), Omron Healthcare, a leading provider of healthcare equipment, has announced a new partnership with JD Healthcare, a subsidiary of China’s e-commerce giant JD.com (NASDAQ: JD). This strategic alliance aims to establish a comprehensive chronic disease management system that integrates both online and…
-
LaNova Medicines and AstraZeneca Ink Global Licensing Deal for GPRC5D-Targeting ADC LM-305
•
Shanghai-based LaNova Medicines Ltd, a developer of cancer therapies, has announced a significant global licensing deal with UK pharmaceutical giant AstraZeneca (AZ, NASDAQ: AZN). The agreement concerns LM-305, a pre-clinical antibody drug conjugate (ADC) that targets GPRC5D. AstraZeneca will receive exclusive global rights to research, develop, and commercialize LM-305, in…
-
ExoRNA Bio Secures Tens of Millions in Financing to Advance Huntington’s Disease Pipeline
•
ExoRNA Bio, a Shenzhen-based central nervous system (CNS) drug developer, has reportedly raised tens of millions of renminbi in an angel+ financing round. The round was led by Yuexiu Industrial Fund, with participation from Jingxin Pharma, Dingxin Capital, Nanjing University Biopharmaceutical Industry Alumni Association, and existing investor CDH Investments. The…
-
Luye Pharma’s Boan Biotechnology Partners with GenScript on GenCircle dsDNA Development
•
Shandong Boan Biotechnology Co., Ltd, a controlling subsidiary of China-based Luye Pharma Group (HKG: 2186), has entered into a strategic partnership with GenScript Biotech Corporation (HKG: 1548), a leading Contract Research Organization (CRO). The collaboration aims to develop and manufacture the small circular double-stranded DNA vector GenCircle dsDNA, which is…
-
Betta Pharmaceuticals and EyePoint Pharmaceuticals Submit EYP-1901 for NMPA Review
•
China’s Betta Pharmaceuticals (SHE: 300558) has announced that the clinical trial filing for its EYP-1901 intravitreal implant, co-filed with EyePoint Pharmaceuticals, Inc (NASDAQ: EYPT), has been accepted for review by the National Medical Products Administration (NMPA). The drug is intended to be assessed as a potential treatment for pathological myopia…
-
Basecare Medical to Acquire BMX Holdco for $40 Million, Expanding IVF Portfolio
•
China-based in vitro fertilization (IVF) specialist, Suzhou Basecare Medical Co., Ltd (HKG: 2170), has announced its intention to acquire 100% stakes in Singapore-headquartered BMX Holdco Pte. Ltd for a sum of $40 million. The acquisition will see BMX becoming a wholly-owned subsidiary of Basecare upon deal closure. BMX Holdco Pte.…
-
Nona Biosciences Partners with PharmaEssentia for Harnessing Harbor Mice Technology
•
Nona Biosciences, a wholly owned subsidiary of Harbour BioMed (HKG: 2142), has announced a strategic partnership with PharmaEssentia Corp.’s R&D center in Boston, United States. The collaboration will fully utilize Nona Bio’s Harbor Mice whole human transgenic mouse platform technology for biomedicine research and development, marking a significant step in…
-
First Condor Biotechnology Secures Tens of Millions in Pre-Series A Financing for CAR-T Cell Trials
•
First Condor Biotechnology, a Guangdong-based cell therapy developer, has reportedly secured tens of millions of renminbi in a Pre-Series A financing round. This funding round was led by Guangdong Lianjing Investment Group, marking a significant step forward for the company. The proceeds from this investment will be directed towards the…
-
Bayer Q1 2023 Financial Report: Sales Dip Amid Regional Challenges and COVID-19 Impact
•
Germany-based Bayer (ETR: BAYN) has released its financial report for the first quarter of 2023, revealing a 1.1% decrease in group sales, excluding exchange effects, to €14.389 billion (USD 15.74 billion). Net profits fell 33.8% year-on-year (YOY) to €2.178 billion, reflecting the ongoing challenges in the pharmaceutical industry. Pharmaceuticals Unit…
-
Wuhan Institute’s Hexavalent Rotavirus Vaccine on Track for Priority Review by CDE
•
The Center for Drug Evaluation (CDE) website has indicated that Wuhan Institute of Biological Products Co., Ltd’s oral hexavalent reconstituted rotavirus live vaccine (Vero cells) is on course for priority review. This priority status is granted for the vaccine’s use in preventing acute gastroenteritis caused by rotavirus in infants and…
-
Kintor Pharmaceutical’s KX-826 Shows Promise in Phase II Study for Male Androgenetic Alopecia
•
China-based Kintor Pharmaceutical Ltd (HKG: 9939) has announced the conclusion of a randomized, double-blind, placebo-controlled Phase II clinical study for its drug candidate KX-826 (pyrilutamide) in the US for the treatment of male patients with androgenetic alopecia (AGA). The study demonstrated that KX-826 can promote hair growth, with statistically and…
-
ZhenGe Biotech Partners with NNIT for Advanced Digitalization in Drug Development
•
ZhenGe Biotech, a China-based Contract Development and Manufacturing Organization (CDMO), has entered into a strategic partnership with NNIT, a Denmark-headquartered provider of digital life sciences solutions. Under the terms of the agreement, NNIT will support ZhenGe in developing a more reliable digitalization platform that offers full lifecycle digital solutions, from…
-
Guangdong Taienkang’s CKBA Ointment for Vitiligo Accepted for Review by China’s NMPA
•
Guangdong Taienkang Pharmaceutical Co., Ltd, (SHE: 301263), a China-based pharmaceutical company, has announced that the National Medical Products Administration (NMPA) has accepted a Phase II clinical trial filing for its CKBA ointment in the treatment of vitiligo. The Category 1 chemical drug is also currently undergoing a Phase IIa clinical…
-
Mabwell’s B7-H3 Targeting ADC 7MW3711 Accepted for Review by China’s NMPA
•
Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062), a China-based biopharmaceutical company, has announced that its clinical trial application for 7MW3711, an antibody drug conjugate (ADC) targeting B7-H3, has been accepted for review by the National Medical Products Administration (NMPA). The drug is intended for the treatment of advanced solid tumors.…
-
CStone Pharmaceuticals’ Partner Servier Secures EU Approvals for IDH1 Inhibitor Tibsovo
•
CStone Pharmaceuticals’ (HKG: 2616) French partner, Servier, has announced receiving two new indication approvals for Tibsovo (ivosidenib), a first-in-class IDH1 inhibitor, from the European Committee. This marks a significant expansion in the drug’s approved uses for treating specific types of leukemia and cholangiocarcinoma. New Indications for Tibsovo in EuropeTibsovo is…
-
Innovent Biologics’ Mazdutide Showcases Weight Loss Efficacy in Phase II Study for Chinese Adults
•
China-based Innovent Biologics Inc., (HKG: 1801), has announced that a Phase II clinical study assessing the higher dose (9mg) of mazdutide (IBI362) in Chinese adults with obesity has achieved its 24-week primary endpoint. This milestone marks a significant step forward in the development of this potential treatment for obesity. Study…
-
Joincare Pharmaceutical Receives NMPA Approval for Triptorelin Microspheres for Prostate Cancer
•
Joincare Pharmaceutical Group Industry Co., Ltd (SHA: 600380), a China-based pharmaceutical company, has announced that it has obtained market approval from the National Medical Products Administration (NMPA) for its triptorelin microspheres. This treatment is designed for prostate cancer patients who require androgen castration therapy. Innovative Treatment Option for Prostate Cancer…
-
Zai Lab’s Repotrectinib on Track for Priority Review by China’s CDE for ROS1+ NSCLC
•
The Center for Drug Evaluation (CDE) website has indicated that Zai Lab Ltd’s (NASDAQ: ZLAB) repotrectinib is on track to receive priority review status in China for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) that is ROS1-positive. This priority review status is a reflection of…
